<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Granulocyte colony-stimulating factor (G-CSF) has had a major impact on management of "severe <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0001875'>neutropenia</z:hpo>," a collective term referring to congenital, idiopathic, or cyclic <z:hpo ids='HP_0001875'>neutropenia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Almost <z:hpo ids='HP_0000001'>all</z:hpo> patients respond to G-CSF with increased neutrophils, reduced <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e>, and improved survival </plain></SENT>
<SENT sid="2" pm="."><plain>Some responders with <z:hpo ids='HP_0005549'>congenital neutropenia</z:hpo> have developed <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> and <z:hpo ids='HP_0004808'>acute myeloblastic leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), which raises the question of the role of G-CSF in pathogenesis </plain></SENT>
<SENT sid="3" pm="."><plain>The Severe <z:hpo ids='HP_0011010'>Chronic</z:hpo> <z:hpo ids='HP_0001875'>Neutropenia</z:hpo> International Registry (SCNIR), Seattle, WA, has data on 696 neutropenic patients, including 352 patients with <z:hpo ids='HP_0005549'>congenital neutropenia</z:hpo>, treated with G-CSF from 1987 to present </plain></SENT>
<SENT sid="4" pm="."><plain>Treatment and patient demographic data were analyzed </plain></SENT>
<SENT sid="5" pm="."><plain>The 352 congenital patients were observed for a mean of 6 years (range, 0.1-11 years) while being treated </plain></SENT>
<SENT sid="6" pm="."><plain>Of these patients, 31 developed <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, for a crude rate of <z:e sem="disease" ids="C1608408" disease_type="Neoplastic Process" abbrv="">malignant transformation</z:e> of nearly 9% </plain></SENT>
<SENT sid="7" pm="."><plain>None of the 344 patients with idiopathic or cyclic <z:hpo ids='HP_0001875'>neutropenia</z:hpo> developed <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>Transformation was associated with acquired marrow cytogenetic clonal changes: 18 patients developed a partial or complete loss of chromosome 7, and 9 patients manifested abnormalities of chromosome 21 (usually <z:mp ids='MP_0004027'>trisomy</z:mp> 21) </plain></SENT>
<SENT sid="9" pm="."><plain>For each yearly treatment interval, the annual rate of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> development was less than 2% </plain></SENT>
<SENT sid="10" pm="."><plain>No significant relationships between age at <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and patient gender, G-CSF dose, or treatment duration were found (P &gt;.15) </plain></SENT>
<SENT sid="11" pm="."><plain>In addition to the 31 patients who developed <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, the SCNIR also has data on 9 additional neutropenic patients whose bone marrow studies show cytogenetic clonal changes but the patients are without transformation to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="12" pm="."><plain>Although our data does not support a cause-and-effect relationship between development of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and G-CSF therapy or other patient demographics, we cannot exclude a direct contribution of G-CSF in the pathogenesis of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="13" pm="."><plain>This issue is unclear because <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> was not seen in cyclic or idiopathic <z:hpo ids='HP_0001875'>neutropenia</z:hpo> </plain></SENT>
<SENT sid="14" pm="."><plain>Improved survival of <z:hpo ids='HP_0005549'>congenital neutropenia</z:hpo> patients receiving G-CSF therapy may allow time for the expression of the leukemic predisposition that characterizes the natural history of these disorders </plain></SENT>
<SENT sid="15" pm="."><plain>However, other factors related to G-CSF may also be operative in the setting of <z:hpo ids='HP_0005549'>congenital neutropenia</z:hpo> </plain></SENT>
<SENT sid="16" pm="."><plain>(Blood </plain></SENT>
<SENT sid="17" pm="."><plain>2000;96:429-436) </plain></SENT>
</text></document>